Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

This study is testing whether combining an immunotherapy drug (penpulimab), a targeted anti-cancer drug (anlotinib), and chemotherapy before surgery can improve outcomes for people with locally advanced esophageal cancer that has not yet spread to distant organs. **You may be eligible if...** - You are between 18 and 75 years old - Your biopsy confirms esophageal cancer and your clinical staging is Stage II–IVA (locally advanced but not distant metastasis) - Your esophageal cancer is not located in the cervical (neck) region - Your major organ functions are within acceptable levels - Your overall health is rated 0–1 on standard performance scales **You may NOT be eligible if...** - You have received prior treatment for this esophageal cancer - You have another active cancer - You have uncontrolled infections or autoimmune conditions - You are pregnant or breastfeeding - You have serious heart conditions or uncontrolled high blood pressure Talk to your doctor to see if this trial is right for you.